GILD Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of 39.21% compared to Gilead Sciences, Inc.'s net margin of 20.83%. Gilead Sciences, Inc.'s return on equity of 41.48% beat Johnson & Johnson's return on equity of 33.27%.

Gilead Sciences, Inc. has a consensus price target of $134.53, signalling downside risk potential of -1.03%. On the other hand Johnson & Johnson has an analysts' consensus of $224.09 which suggests that it could grow by 1.79%. Given that Johnson & Johnson has higher upside potential than Gilead Sciences, Inc., analysts believe Johnson & Johnson is more attractive than Gilead Sciences, Inc..

Gilead Sciences, Inc. has a beta of 0.334, which suggesting that the stock is 66.568% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.341, suggesting its less volatile than the S&P 500 by 65.861%.

Gilead Sciences, Inc. has a quarterly dividend of $0.79 per share corresponding to a yield of 2.33%. Johnson & Johnson offers a yield of 2.34% to investors and pays a quarterly dividend of $1.30 per share. Gilead Sciences, Inc. pays 805.23% of its earnings as a dividend. Johnson & Johnson pays out 46.59% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Gilead Sciences, Inc.'s is not.

Gilead Sciences, Inc. quarterly revenues are $7.8B, which are smaller than Johnson & Johnson quarterly revenues of $24.6B. Gilead Sciences, Inc.'s net income of $3.1B is lower than Johnson & Johnson's net income of $5.1B. Notably, Gilead Sciences, Inc.'s price-to-earnings ratio is 21.05x while Johnson & Johnson's PE ratio is 19.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gilead Sciences, Inc. is 5.88x versus 5.67x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of 39.21% compared to Gilead Sciences, Inc.'s net margin of 31.72%. Gilead Sciences, Inc.'s return on equity of 41.48% beat Eli Lilly & Co.'s return on equity of 106.26%.

Gilead Sciences, Inc. has a consensus price target of $134.53, signalling downside risk potential of -1.03%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,110.72 which suggests that it could grow by 4.36%. Given that Eli Lilly & Co. has higher upside potential than Gilead Sciences, Inc., analysts believe Eli Lilly & Co. is more attractive than Gilead Sciences, Inc..

Gilead Sciences, Inc. has a beta of 0.334, which suggesting that the stock is 66.568% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.348, suggesting its less volatile than the S&P 500 by 65.185%.

Gilead Sciences, Inc. has a quarterly dividend of $0.79 per share corresponding to a yield of 2.33%. Eli Lilly & Co. offers a yield of 0.56% to investors and pays a quarterly dividend of $1.50 per share. Gilead Sciences, Inc. pays 805.23% of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Gilead Sciences, Inc.'s is not.

Gilead Sciences, Inc. quarterly revenues are $7.8B, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Gilead Sciences, Inc.'s net income of $3.1B is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Gilead Sciences, Inc.'s price-to-earnings ratio is 21.05x while Eli Lilly & Co.'s PE ratio is 52.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gilead Sciences, Inc. is 5.88x versus 16.33x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of 39.21% compared to Gilead Sciences, Inc.'s net margin of 33.68%. Gilead Sciences, Inc.'s return on equity of 41.48% beat Merck & Co., Inc.'s return on equity of 39.63%.

Gilead Sciences, Inc. has a consensus price target of $134.53, signalling downside risk potential of -1.03%. On the other hand Merck & Co., Inc. has an analysts' consensus of $115.33 which suggests that it could grow by 6.61%. Given that Merck & Co., Inc. has higher upside potential than Gilead Sciences, Inc., analysts believe Merck & Co., Inc. is more attractive than Gilead Sciences, Inc..

Gilead Sciences, Inc. has a beta of 0.334, which suggesting that the stock is 66.568% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.291, suggesting its less volatile than the S&P 500 by 70.859%.

Gilead Sciences, Inc. has a quarterly dividend of $0.79 per share corresponding to a yield of 2.33%. Merck & Co., Inc. offers a yield of 3.03% to investors and pays a quarterly dividend of $0.85 per share. Gilead Sciences, Inc. pays 805.23% of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Gilead Sciences, Inc.'s is not.

Gilead Sciences, Inc. quarterly revenues are $7.8B, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Gilead Sciences, Inc.'s net income of $3.1B is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Gilead Sciences, Inc.'s price-to-earnings ratio is 21.05x while Merck & Co., Inc.'s PE ratio is 14.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gilead Sciences, Inc. is 5.88x versus 4.27x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of 39.21% compared to Gilead Sciences, Inc.'s net margin of 38.89%. Gilead Sciences, Inc.'s return on equity of 41.48% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.

Gilead Sciences, Inc. has a consensus price target of $134.53, signalling downside risk potential of -1.03%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $830.04 which suggests that it could grow by 10.15%. Given that Regeneron Pharmaceuticals, Inc. has higher upside potential than Gilead Sciences, Inc., analysts believe Regeneron Pharmaceuticals, Inc. is more attractive than Gilead Sciences, Inc..

Gilead Sciences, Inc. has a beta of 0.334, which suggesting that the stock is 66.568% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.390, suggesting its less volatile than the S&P 500 by 60.965%.

Gilead Sciences, Inc. has a quarterly dividend of $0.79 per share corresponding to a yield of 2.33%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.47% to investors and pays a quarterly dividend of $0.88 per share. Gilead Sciences, Inc. pays 805.23% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Gilead Sciences, Inc. quarterly revenues are $7.8B, which are larger than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. Gilead Sciences, Inc.'s net income of $3.1B is higher than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, Gilead Sciences, Inc.'s price-to-earnings ratio is 21.05x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gilead Sciences, Inc. is 5.88x versus 5.83x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.